Deciding on second- or third-line erlotinib in stage IV non-small-cell lung cancer (NSCLC) patients (P) based on the presence of mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)

被引：0
|
作者：
Porta, Rut
Terrasa, Josefa
Rolfo, Cristian
Gonzalez Larriba, Jose Luis
Garcia Campelo, Rosario
Mesia, Carlos
Pallares, Cinta
Lianes, Pilar
Queralt, Cristina
Rosell, Rafael
机构：
[1] Hosp Josep Trueta, Med Oncol Serv, Catalan Inst Oncol, Girona, Spain
[2] Hosp Son Dureta, Med Oncol Serv, Mallorca, Spain
[3] Med Oncol Serv, Clin Rotger, Mallorca, Spain
[4] Hosp Clin Madrid, Med Oncol Serv, Madrid, Spain
[5] Hosp Juan Canalejo, Med Oncol Serv, La Coruna, Spain
[6] Hosp del Mar, Med Oncol Serv, Barcelona, Spain
[7] Hosp Santa Creu & Sant Pau, Med Oncol Serv, Barcelona, Spain
[8] Hosp Mataro, Med Oncol Serv, Mataro, Spain
[9] Hosp Germans Trias & Pujol, Med Oncol Serv, Catalan Inst Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：215 / 216
页数：2
相关论文
共 50 条
  • [1] Deciding on second- or third-line erlotinib in stage IV non-small cell lung cancer (NSCLC) patients (pts) based on the presence of mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Reguart, N.
    Insa, A.
    Bover, I.
    Ibeas, R.
    Camps, C.
    Diz, P.
    Martinez del Prado, P.
    Terrasa, J.
    Queralt, C.
    Rosell, R.
    [J]. LUNG CANCER, 2006, 52 : S27 - S28
  • [2] First-line erlotinib in stage IV non-small-cell lung cancer (NSCLC) patients (P) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Massuti, Bartomeu
    Reguart, Noemi
    Vivanco, Guillermo Lopez
    Provencio, Mariano
    Isla, Dolores
    Camps, Carlos
    Ares, Luis Paz
    Pradas, Anna
    Taron, Miquel
    Rosell, Rafael
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 216 - 216
  • [3] Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) and response to first-line erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p)
    Reguart-Aransay, Noemi
    Mayo, Clara
    Queralt, Cristina
    Botia, Monica
    Pastor, Carmen
    Perez, Maria
    Catot, Silvia
    Prada, Anna
    Galvez, Marc
    Taron, Miquel
    Rosell, Rafael
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [4] First-line erlotinib in stage IV non-small cell lung cancer (NSCLC) patients (pts) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Massuti, B.
    Porta, R.
    Paz-Ares, L.
    Cardenal, F.
    Lopez-Vivanco, G.
    Provencio, M.
    Isla, D.
    Pradas, A.
    Taron, M.
    Rosell, R.
    [J]. LUNG CANCER, 2006, 52 : S25 - S26
  • [5] Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)
    Porta, R.
    Queralt, C.
    Cardenal, F.
    Mayo, C.
    Provencio, M.
    Camps, C.
    Isla, D.
    Gonzalez-Larriba, J.
    Taron, M.
    Rosell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR).
    Paz-Ares, L.
    Sanchez, J. M.
    Garcia-Velasco, A.
    Massuti, B.
    Lopez-Vivanco, G.
    Provencio, M.
    Montes, A.
    Isla, D.
    Amador, M. L.
    Rosell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 369S - 369S
  • [7] Epidermal growth factor receptor (EGFR) activating mutations (muts) in the tyrosine kinase (TK) domain correlate with gefitinib response in chemorefractory non-small-cell lung cancer (NSCLC).
    Taron, M
    Ichinose, Y
    Rosell, R
    Mok, T
    Massuti, B
    Manegold, C
    Queralt, C
    Jahan, T
    Hsue, V
    Jablons, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 642S - 642S
  • [8] Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
    Papadimitrakopoulou, Vassiliki A.
    Soria, Jean-Charles
    Jappe, Annette
    Jehl, Valentine
    Klimovsky, Judith
    Johnson, Bruce E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) : 1594 - 1601
  • [9] Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations
    Matsuura, Shun
    Inui, Naoki
    Ozawa, Yuichi
    Nakamura, Yutaro
    Toyoshima, Mikio
    Yasuda, Kazumasa
    Yamada, Takashi
    Shirai, Toshihiro
    Suganuma, Hideki
    Yokomura, Koji
    Suda, Takafumi
    Chida, Kingo
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (08) : 959 - 963
  • [10] Multicenter prospective study of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations
    Cardenal, Felipe
    Moran, Teresa
    Queralt, Cristina
    Porta, Ruth
    Camps, Carlos
    Majem, Margarita
    Lopez-Vivanco, Guillermo
    Isla, Dolores
    Provencio, Mariano
    Sanchez, Jose Javier
    Taron, Miquel
    Rosell, Rafael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S324 - S325
12345